The Latest Breaking News from Compass

Patents are the golden eggs of the booming psychedelic space.

Staff and patients at St John's may lose the hospital's shop as no company has yet to take up the lease on the small retail outlet

Analysts have provided the following ratings for Compass (NYSE:COMP) within the last quarter:

Compass (NYSE:COMP) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Compass beat estimated earnings by 6.25%, reporting an EPS of $-0.45 versus an estimate of $-0.48.

Don’t write off Ocado in very long term – but reversal also points to one of the stock market’s terrible habits

Compass Pathways (NASDAQ: CMPS) announced its financial results for the first quarter of 2022, which ended March 31. Q1 Results For the first three months of the year, net loss was $21.2 million, or $0.50 loss per share. For comparison, net loss in the same period of 2021 was $12.7 million…

Psychedelics continue to garner attention as possible treatments for diverse mental health conditions. Now, Compass Pathways (NASDAQ: CMPS) will undertake a study to evaluate psilocybin’s effects on autistic adults.

Ahead of the speech, a coalition of campaign groups set out its own wish list for strengthening British democracy

Australian voters are split on many issues but there's strong agreement on who should own Australian farms — and it's not foreigners.

Compass Pathways (Nasdaq: CMPS), a company developing psychedelic pharmaceutical drugs for the mental health space, announced the publication of two new investigator-initiated studies using its flagship compound, COMP360.

Informal alliances between progressive parties help win seats. There’s no shame in working together, says Neal Lawson, director of campaign group Compass